CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 150 enrolled
Drug / intervention
Miltenyi CliniMACS® CD34 Reagent Systemdevice
Likely dose
Miltenyi CliniMACS® CD34 Reagent System — CD34+ enriched/T-cell depleted cells from haploidentical mobilized peripheral blood combined with single unit umbilical cord bloodAI-extracted
Key inclusion· 5
  • ✓Ages 18–80 years inclusive
  • ✓Diagnosed with high-risk hematologic disorder warranting stem cell transplant per institutional standard of care
  • ✓Lack HLA-identical related donor
  • ✓Availability of at least one HLA-haploidentical (≥5/10 and ≤8/10 HLA match) related donor able to donate CD34+ cells
Key exclusion· 2
  • ✕HLA-identical (6/6) related donor available and readily accessible at time of transplantation evaluation
  • ✕Does not meet institutional standard guidelines for transplant eligibility

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03093844
NCT03093844N/ACompleted
CompareCT.gov

Safety and Efficacy of Miltenyi CliniMACS® CD34 Reagent System for Transplant Protocol Utilizing Haploidentical CD34+ Selected Cells Combined With Single Unit Umbilical Cord Blood Transplant for Treatment of High-risk Hematologic Disorders

University of Colorado, Denver·interventional·Posted Mar 28, 2017·Updated Aug 15, 2025

In Brief

A clinical study evaluating Miltenyi CliniMACS® CD34 Reagent System for Hematologic Disorders. Completed, enrolled 150 participants across 1 site.

Detailed Summary

This is a study to evaluate the safety and efficacy of Miltenyi CliniMACS® CD34 Reagent System to promote engraftment of haploidentical CD34+ selected cells combined with single unit umbilical cord blood transplant for treatment of high-risk hematologic disorders.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematologic Disorders
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMar 28, 2017
Enrollment StartOct 12, 2017
Primary CompletionNov 27, 2024
Study CompletionFeb 5, 2025
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 9.3 years ago

Interventions

Miltenyi CliniMACS® CD34 Reagent Systemdevice

Miltenyi CliniMACS® CD34 Reagent System will be used to prepare CD34+ enriched/T-cell depleted cells from haploidentical mobilized peripheral blood.